Physician profile
Christopher O Harper
NPI 1770575854
$5,442.65
in general payments reported to CMS, 2019-2025
35 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $979 · 2021: $1,463 · 2022: $745 · 2023: $547 · 2024: $645 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $823.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.39 | 2019-2024 | Synjardy, Jardiance |
| Abbvie INC. | $565.26 | 2019-2025 | |
| Amgen INC. | $519.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $336.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $326.33 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $305.17 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $291.04 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.19 | 2021-2025 | |
| Allergan, INC. | $170.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $166.32 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $131.83 | 2019-2021 | |
| Grifols USA, LLC | $101.38 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.62 | 2019-2021 | |
| Corcept Therapeutics | $79.41 | 2022-2025 | Korlym |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.50 | 2020-2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $57.61 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $57.33 | 2021 | |
| Esperion Therapeutics, INC. | $57.09 | 2020-2021 | |
| Dexcom, INC. | $51.84 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.13 | 2020-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $39.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.68 | 2020-2022 | |
| Depuy Synthes Sales INC. | $37.21 | 2023 | Orthovisc |
| Radius Health, INC. | $30.14 | 2019-2020 | |
| Preventice Services, LLC | $26.17 | 2020 | |
| Alnylam Pharmaceuticals INC. | $23.60 | 2024 | Givlaari |
| Celgene Corporation | $20.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.44 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2024 | Caplyta |
| Exact Sciences Corporation | $15.95 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $15.94 | 2021 | |
| Merck Sharp & Dohme LLC | $15.18 | 2019 | |
| Boston Scientific Corporation | $14.88 | 2023 | |
| Amarin Pharma, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.